In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Incyte Corporation used $675.3 million of cash from operations, down 220.7% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
98
+7.0%
|
24
+0.6%
|
26
+15.5%
|
24
+6.4%
|
24
+5.5%
|
24
+6.7%
|
23
+4.0%
|
22
+1.9%
|
23
+4.5%
|
| Stock-based compensation |
263
+1.7%
|
70
+13.3%
|
67
+4.1%
|
64
+5.2%
|
62
-13.3%
|
62
-20.9%
|
65
+14.1%
|
61
+2.0%
|
72
+19.5%
|
| Operating cash flow |
745
-40.5%
|
-675
-220.7%
|
508
+1034.7%
|
369
+38.8%
|
543
+42.5%
|
559
+79.9%
|
45
+107.8%
|
266
+21.6%
|
381
+158.1%
|
| Investing | |||||||||
| Investing cash flow |
-222
-155.9%
|
-44
+6.5%
|
-52
-174.4%
|
-88
-8140.4%
|
-37
-74.3%
|
-47
-223.9%
|
-19
-108.8%
|
1
+101.5%
|
-21
+86.1%
|
| Financing | |||||||||
| Stock buybacks |
—
|
—
|
—
|
—
|
0
|
0
-100.0%
|
0
-100.0%
|
—
|
0
|
| Financing cash flow |
302
+1951.8%
|
14
+209.1%
|
65
+682.0%
|
85
+769.2%
|
138
+575.4%
|
-13
+60.5%
|
-11
+99.4%
|
-13
-2.1%
|
20
+5794.2%
|
| Change in cash | |||||||||
| Effect of exchange rate |
-4
-272.7%
|
-1
-198.8%
|
-0
+93.0%
|
-3
-387.1%
|
-1
-123.2%
|
1
+557.0%
|
-1
-9307.7%
|
-1
+18.3%
|
3
+147.4%
|
| Net change in cash |
821
-28.7%
|
-707
-241.3%
|
521
+3782.3%
|
363
+43.1%
|
643
+67.6%
|
500
+57.8%
|
13
+100.6%
|
254
+91.5%
|
384
+2894.7%
|
| Shareholder returns | |||||||||
| Returned to shareholders |
—
|
—
|
—
|
—
|
0
|
0
|
0
|
—
|
0
|
| Ratios | |||||||||
| Stock-based compensation to revenue |
4.38%
|
4.48%
|
4.02%
|
5.04%
|
4.13%
|
4.51%
|
5.32%
|
5.79%
|
6.08%
|
| Cash conversion |
1.85x
|
—
|
0.87x
|
1.22x
|
1.82x
|
1.32x
|
0.11x
|
1.68x
|
1.89x
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- INCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879169
- Former names
- INCYTE INC (until Mar 28, 2003); INCYTE GENOMICS INC (until Feb 25, 2003); INCYTE PHARMACEUTICALS INC (until Apr 18, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.